Archive Course Catalog

Published 12/21/2022

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This interactive course, Toxicity Management provides information on incidence, onset, severity, and grading of immune-related toxicities and irAEs with immune checkpoint inhibitors. Dr. Alexa Meara and Dr. Pankti Reid have also presented cases focussing irAEs, treatment plan, and management. 

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: December 21, 2022 - December 21, 2023

Estimated time to complete activity: 90 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the end of this activity, the participant should be able to:

• Identify immune-related toxicities by grade, onset, and incidence.
• Identify immune-related adverse events resulting from immune checkpoint inhibitors.
• Describe the adverse events and management of cellular therapies.
• Describe the precautions needed when immunotherapy is provided to special patient populations.

Faculty

Alexa S. Meara, MD

Associate Professor

Division of Oncology

Division Rheumatology and Immunology

The Ohio State Wexner Medical Center, Ohio

Pankti Reid, MD, MPH

Assistant Professor

University of Chicago Medical Center, Illinois

Department of Medicine- Division of Rheumatology

Committee on Clinical Pharmacology and Pharmacogenomics

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
 

Alexa Meara, MD - Consultant/Advisor/Speaker:  Abbvie, GSK, Amgen, Sanofi, Aurinia

Pankti Reid, MD - Royalty and Patent Beneficiary: Patent pending for use of interleukin 6 axis inhibitor for viral infection associated pneumonitis  

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit

During the period 12/21/2022 through 12/21/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of  1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hour. Designated for 1 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour (1.5 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-494-H01-P

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 5/20/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Immune Checkpoint Inhibitors. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: May 20, 2022 - May 20, 2023

Estimated time to complete activity: 3.75 hours

Faculty: 

Marina Chiara Garassino, MD - The University of Chicago

Natalie Vokes, MD - The University of Texas MD Anderson Cancer Center

Jarushka Naidoo, MBBCH, MHS - Beaumont RCSI Cancer Centre, Dublin

Diane Tseng, MD, PhD - University of Washington School of Medicine, Fred Hutchinson Cancer Research Center

Bonnie Bermas, MD - UT Southwestern Medical Center

Vickie Shannon, MD - The University of Texas MD Anderson Cancer Center

Sadia Ali, MD - UT Southwestern Medical Center

Nikhil I. Khushalani, MD - Moffitt Cancer Center

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the mechanisms of immune checkpoint inhibitors.
• Summarize recent updates in the use of immune checkpoint inhibitors clinically.
• Outline common toxicities with immune checkpoint inhibitors and their management.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-240-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This course is no longer available for credit.

Published May 23, 2022

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This interactive course provides an overview of the mechanisms of immune-related adverse events (irAEs) that may be caused by implementing cancer immunotherapy.  This module walks the learner through the various mechanisms of irAEs, as well as differentiating early and late irAEs which may be distinguished by distinct mechanisms.  Learners will also have the opportunity to apply the knowledge gained in this module through two case studies.  

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: May 23, 2022 - May 23, 2023

Estimated time to complete activity: 15 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify the various mechanisms of irAEs as well as the types of irAEs that may result.
• Describe various irAEs as well as treatment for severe irAEs.
• Differentiate central vs. peripheral tolerance of irAEs.

Faculty
Pradnya Patil, MD, FACP

Associate Staff / Department of Hematology-Oncology

Cleveland Clinic, Cleveland

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Pradnya Patil, MD, FACP - Nothing to disclose.

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period May 23, 2022 through May 23, 2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of  0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. 

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-279-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 3/24/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Skin Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: March 24, 2022 - March 24, 2023

Estimated time to complete activity: 3.75 hours

Faculty:

Allison Betof Warner, MD, PhD - Memoral Sloan Kettering Cancer Center

Isabella C. Glitza, MD, PhD - The University of Texas MD Anderson Cancer Center

Janice Mehnert, MD - NYU Langone Health

Michael K. Wong - MD, PhD - The University of Texas MD Anderson Cancer Center

Ryan J. Sullivan, MD - Harvard Medical School, Massachusetts General Hospital

Omid Hamid, MD - The Angeles Clinic and Research Institute

Jarushka Naidoo, MBBCH, MHS - Beaumont RCSI Cancer Centre Dublin

Kathy Madden, NP, RN, MSN, FNP-BC, AOCNP, APHN - NYU Langone Perlmutter Cancer Center

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify the cancer immunotherapy approaches in use for the treatment of skin cancers.
• Summarize recent updates in cancer immunotherapy for skin cancers, including emerging toxicities and managment.
• Implement cancer immunotherapy for skin cancer into clinical pratice appropriately.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number  - JA4008162-9999-22-130-H01-P

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 2/24/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Intratumoral Therapies, Vaccines, and Cytokines. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: February 24, 2022 - February 24, 2023

Estimated time to complete activity: 3.75 hours

Faculty: 

Diwakar Davar, MMBBS, MSc - UPMC Hillman Cancer Center

Patrick Ott, MD, PhD - Dana Farber Cancer Institute

Adi Diab, MD - The University of Texas MD Anderson Cancer Center

Harriet Kluger, MD - Yale School of Medicine

Matthew J. Frigault, MD, MSc - Massachusetts General Hospital

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the mechanisms of intratumoral therapies, vaccines, and cytokines.
• Summarize recent updates in the use of intratumoral therapies, vaccines, and cytokines clinically.
• Outline common toxicities with intratumoral therapies, vaccines, and cytokines, and their management.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-073-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 2/9/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Head and Neck Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: February 9, 2022 - February 9, 2023

Estimated time to complete activity: 3.75 hours

Faculty: 

Jessica R. Bauman, MD - Fox Chase Cancer Center

Jessica L. Geiger, MD - Cleveland Clinic Cancer Center

Dan P. Zandberg, MD - UPMC Hillman Cancer Center

Tanguy Seiwert, MD - Johns Hopkins Medicine

Trisha Wise-Draper, MD, PhD - University of Cincinnati Cancer Center

Ranee Mehra, MD - University of Maryland

Ravindra Uppaluri, MD, PhD - Dana Farber Cancer Institute and Brigham and Women's Hospital

Sana Karam, MD, PhD - University of Colorado

Aarti Bhatia, MD - Yale School of Medicine

Sid Sheth, MD - UNC School of Medicine

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify the cancer immunotherapy approaches in the use for the treatment of head and neck cancers.
• Summarize recent updates in cancer immunotherapy for head and neck cancers as well as toxicity management for key disease states.
• Implement cancer immunotherapy for head and neck cancers into clinical practice appropriately.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-052-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Published: On Date

Please note, this activity does not offer continuing education credit.

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Additional support for this activity provided by:

Course Description and Target Audience
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, advanced practitioners, emergency physicians and all members of the cancer team, the ACI program focuses on how to educate your patients about receiving inpatient/outpatient cellular therapies; including examples of practical implementation provided

Estimated time to complete activity: 25 Minutes

Learning Objectives
At the conclusion of this activity, the participant should be able to:

• Understand the patient journey and how to prepare a patient for these steps.

• To be informed of the many time points that require patient education and reinforcement.

• Develop an understanding about the varying pieces of education necessary for patient success.

• How to properly prepare patients and their caregivers for outpatient CAR-T cell therapy.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

Faculty and Disclosure of Conflicts of Interest

No relevant financial conflicts.

Faculty
Meaghan Ekstrom, BA, BSN, MSN, FNP-BC
Massachusetts General Hospital
Boston, MA

The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Published Date: 12/01/2023

Expiration Date: 12/01/2024

Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. In the course Difficult-to-treat Cases, Subject Matter Expert- David A. Braun, MD, PhD of Yale School of Medicine has endorsed the effectiveness of Immunotherapy in treating patients with Renal Cell Carcinoma. There are 3 real life difficult to treat case scenarios that elaborate tests, treatment plans, and the outcomes. The Subject Matter Expert reinforced his treatment plans while sharing the risk factors involved using the results of various clinical trials.

View all available ACI online offerings at www.sitcancer.org/acionline.

Estimated time to complete the activity: 45 minutes

For additional information about the accreditation of this activity, please visit https://partnersed.com

Hardware and Software Requirements
SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
 

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

Educational Objectives:                                                  

Upon completion of this activity, participants should be able to:

• Identify the benefits and risks of adjuvant immune checkpoint inhibitor (ICI) therapy with help of case studies.
• Recognize the differences between front-line ICI-based therapies for metastatic disease.
• Explain the treatment options for “PD-1—refractory” disease.

Faculty and Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty:

David A. Braun, MD, PhD       

Assistant Professor, Goodman and Gilman Yale Scholar- Yale Cancer Center, Yale School of Medicine

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

Conflicts of Interest:
Consultant/Advisor/Speaker: Exelixis, AVEO, Charles River Associates, Schlesinger Associates, Imprint Science, Insight Strategy, Trinity Group, Cancer Expert Now, Adnovate Strategies, MDedge, CancerNetwork, Catenion, OncLive, Cello Health BioConsulting, PWW Consulting, Haymarket Medical Network, Aptitude Health, ASCO Post/Harborside, Targeted Oncology, AbbVie.

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

Pharmacy Continuing Education

PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008073-9999-23-305-H01-P)

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Instructions for Credit

During the period 12/01/2023 through 12/01/2024, participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 75% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Published: On 10/05/2023

Please note, this activity does not offer continuing education credit.

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Additional support for this activity provided by:

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

The course irAES associated with Cellular Therapies and T-cell Engagers starts with an overview of cellular therapies and bisepcific antibodies. Dr. Loretta Nastoupil of UT MD Anderson Cancer Center has described the immune related acute and late adverse events associated with CAR T-cell therapies and potential approches to management of toxicities. The case studies presented by Dr. Nastoupil help decide the best possible action plan for managing toxicities associated with CAR T-cell therapies in patients.

Estimated time to complete activity:  40 Minutes

Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives
At the conclusion of this activity, the participant should be able to:

• Give a brief overview of the mechanism of action and common toxicities associated with cellular therapies and T cell engagers.

• List the multiple approaches that should be followed post treatment.

• Describe the immune related acute and late adverse events (toxicities) associated with CAR-T cell therapies.

• Describe similar acute toxicities associated with T-cell engagers and potential different approaches to management.

• Explain the action plan for the management of toxicities associated with CAR-T cell therapies.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

Faculty and Disclosure of Conflicts of Interest

Faculty
Loretta Nastoupil, MD
Associate Professor
UT MD Anderson Cancer Center
Texas, USA

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

Conflicts of Interest
Researcher: BMS, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech, Gilead/Kite, IGM Biosciences, Janssen, Novartis, Takeda
Consultant/ Advisor/ Speaker: Abbvie, Atara, BMS, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech, Gilead/Kite, Janssen, Merck, Novartis, Takeda

The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Published: On 08/11/2023

Please note, this activity does not offer continuing education credit.

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Additional support for this activity provided by:

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

The course- Combination therapies in Combating Cancer gives a brief overview of the several combination therapies such as Inhibitory Immune Checkpoint Combination therapy, Targeted Immunotherapy approches, and other emerging combination therapies. In this course, the subject matter expert describes the effectiveness of various combination immunotherpy approches and their outcomes in cancer patients using several case studies and research papers. The course content emphasizes the emerging landscape of combining immunotherapy with different modalities to treat cancer. 

View all available ACI online offerings at www.sitcancer.org/acionline.

Estimated time to complete activity:  1 hour

Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives
At the conclusion of this activity, the participant should be able to:

• Describe key immunotherapy targets that are useful for combination approaches.
• Describe immunotherapy-based combination treatment regimens currently under investigation.
• Discuss the emerging landscape of combining immunotherapy with different modalities to treat cancer.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

Faculty
Gregory B. Lesinski, PhD, MPH
Co-Director, Translational GI Malignancy Program
Winship Cancer Institute of Emory University,
Atlanta, Georgia, USA

Disclosure of Conflicts of Interest
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
Gregory B. Lesinski, PhD, MPH: Works at a Academic Medical Center and a consultant advisor speaker for Bristol-Myers Squib, Vaccinex, Boerhinger-Ingelheim, Merck and Co.

The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 

Published Date: 06/30/2023

Expiration Date: 06/30/2024

Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Introduction to Biomarkers provides an overview on types of biomarkers and its significance in treatment of cancer. The SME has discussed various findings and outcomes of the clinical trial initiatives related to biomarkers.

View all available ACI online offerings at www.sitcancer.org/acionline.

Estimated time to complete the activity: 45 minutes

For additional information about the accreditation of this activity, please visit https://partnersed.com

Hardware and Software Requirements
SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
 

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

Educational Objectives:                                                  

Upon completion of this activity, participants should be able to:

• Define the term biomarker.
• Explain the functions of biomarkers.
• Differentiate the biomarkers based on their types.
• Describe the use of biomarkers in various cancer treatments.
• Summarize the challenges of using biomarkers in the treatment of cancer.

Faculty and Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty:

Dr. Paolo A. Ascierto, MD
Director of Department of Melanoma
UOC Melanoma, Immunoterapia Oncologica e Terapie Innovative
Istituto Nazionale Tumori – Fondazione “G. Pascale”
Napoli, Italy

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

Conflicts of Interest:
Researcher: Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi
Consultant/Advisor/Speaker: Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, Replimmune, Bayer

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

Pharmacy Continuing Education

PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008073-9999-23-162-H01-P)

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Instructions for Credit

During the period 06/30/2023 through 06/30/2024, participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Published Date: 06/01/2023

Expiration Date: 06/01/2024

Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Mechanisms of Immune-related Adverse Events (irAEs) provides an insight into the host factors that increase the risk of irAEs. The course briefly explains the differences in toxicities of CTLA-4 and PD-1 immune checkpoint inhibitors. The two case studies presented in course enables the learners to assess the immune-related response of immunotherapy treatment in a patient.

View all available ACI online offerings at www.sitcancer.org/acionline.

Estimated time to complete the activity: 45 minutes

For additional information about the accreditation of this activity, please visit https://partnersed.com

Hardware and Software Requirements
SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
 

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

Educational Objectives:                                                  

Upon completion of this activity, participants should be able to:

• Explain the Mechanisms of immune related Adverse Events in brief.
• Describe the other host factors that affect the risk of immune related Adverse Events.
• Summarize the differences in PD-L1 and CTLA-4 toxicities.
• Explain the response assessment process in a patient for the immunotherapy treatment.

Faculty and Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty:

Pradnya Patil, MD, FACP
Associate Staff Oncologist
Taussig Cancer Center, Cleveland Clinic
Cleveland, OH

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

Conflicts of Interest:
Consultant/Advisor/Speaker: AstraZeneca, Jazz Pharmaceuticals

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

Pharmacy Continuing Education

PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008073-9999-23-151-H01-P)

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Instructions for Credit

During the period 06/01/2023 through 06/01/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Published Date: 05/05/2023

Expiration Date: 05/05/2024

Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team. The ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

This course, Introduction to Immunology provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy.

View all available ACI online offerings at www.sitcancer.org/acionline.

Estimated time to complete the activity: 1 hour

For additional information about the accreditation of this activity, please visit https://partnersed.com

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
 

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

Educational Objectives:                                                  

Upon completion of this activity, participants should be able to:

• Describe the function of the components of the immune system, including relevant cells, molecules, and organs of the immune system.
• Differentiate between the adaptive immune system and the innate immune system.
• Recognize the barriers to effective immunotherapy, including mechanism by which tumors locally disable and/or evade the immune system.

Faculty and Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty:

Chrystal M. Paulos, PhD
Director of Translational Research, Cutaneous Malignancies
Winship Cancer Institute at Emory University

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

Conflicts of Interest:
IP Rights: Ares Immunotherapy
Consulting Fees: Ares Immunotherapy
Founder/Owner: Ares Immunotherapy
Other (subcontracts): Obsidian, Lycera, ThermaFisher

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses. 

Pharmacy Continuing Education

PACE designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008073-9999-23-142-H01-P)

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Instructions for Credit

During the period 05/05/2023 through 05/05/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Published: On 04/28/2023

Please note, this activity does not offer continuing education credit.

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Additional support for this activity provided by:

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

This course, Basic Principles of Cancer Immunotherapy will walk the learner through the biological foundations of immunotherapy, types of immunotherapies, illustrate how biomarkers play a major role in immunotherapy, as well as cover the patient response to immunotherapy and subsequent physician assessment.  

View all available ACI online offerings at www.sitcancer.org/acionline.

Estimated time to complete activity:  1 hour

Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives
At the conclusion of this activity, the participant should be able to:

• Describe the concept of Immunotherapy.
• Identify the various types of cancer immunotherapy.
• Describe the rationale for common approaches to cancer immunotherapy.
• Explain the response assessment process in a patient for the immunotherapy treatment.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

Faculty
Christian M. Capitini, MD
Associate Professor
University of Wisconsin-Madison

Disclosure of Conflicts of Interest
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
Christian M. Capitini, MD: Works at a Academic Medical Center and a consultant advisor speaker for Bayer, Elephas, Novartis, Nektar Therapeutics, WiCell Research Institute

The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

Join Thomas Powles, MBBS, MRCP, MD, Andrea Necchi, MD, and Cora N. Sternberg, MD, FACP in a discussion on the role of immunotherapy in urotherlial carcinoma.

This educational activity is intended for an international audience of non-US hematologists/oncologists and urologists. The goal of this activity is to increase oncologists' and urologists' understanding of the role of immunotherapy in the treatment of locally advanced or metastatic urothelial carcinoma.
 

Learning Objectives:

Upon completion of this activity, participants will:

• Have increased knowledge regarding the
  • Available immunotherapy strategies for locally advanced/metastatic urothelial carcinoma
  • Supporting evidence for immunotherapy strategies for locally advanced/metastatic urothelial carcinoma
• Have greater competence related to
  • Selecting the right immunotherapy strategy for the right patient with locally advanced/metastatic urothelial carcinoma

Approximate Time to Complete: 30 minutes

Credit Available: March 11, 2022 - March 11, 2023

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

Join Hossein Borghaei, DO, MS, Ramaswamy Govindan, MD, Charu Aggarwal, MD, MPH, and Jarushka Naidoo, MBBCh in a discussion on the role of immunotherapy in advanced non-small cell lung cancer without targetable mutations.

This activity is intended for hematologists/oncologists, pulmonologists, and pathologists.

The goal of this activity is that learners will have an increased awareness of immunotherapeutic regimens as first-line treatment for NSCLC and be better able to identify and manage immune-related adverse events using a multidisciplinary approach.
 

Learning Objectives:

• Have increased knowledge regarding the
  • Rationale for using immunotherapy in early-stage NSCLC
  • Key clinical trial data evaluating immunotherapy in the treatment of early-stage NSCLC
• Demonstrate greater confidence in their ability to
  • Understanding of the latest data on immunotherapy in the treatment of early-stage NSCLC

Approximate Time to Complete: 30 minutes

Credit Available: March 11, 2022 - March 11, 2023

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

Dr Borghaei and Dr Chaft join to discuss recent clinical data supporting the use of immunotherapy in early-stage NSCLC.

The goal of this activity is to provide insight on the rationale and clinical trial data for immunotherapy in the treatment of patients with early-stage non-small cell lung cancer (NSCLC).

This activity is intended for oncologists, pulmonologists, and pathologists.

Learning Objectives:

• Have increased knowledge regarding the
  • Rationale for using immunotherapy in early-stage NSCLC
  • Key clinical trial data evaluating immunotherapy in the treatment of early-stage NSCLC
• Demonstrate greater confidence in their ability to
  • Understanding of the latest data on immunotherapy in the treatment of early-stage NSCLC

Approximate Time to Complete: 30 minutes

Credit Available: February 25, 2022 - February 25, 2023

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

Drs Weiss and Burtness discuss the latest immunotherapeutic strategies in the management of head and neck cancers.

The goal of this initiative is to update clinicians about the evidence base on cancer immunotherapies, including the role of biomarkers, and provide guidance on applying these data to improve performance and increase confidence in integrating immunotherapeutic regimens into practice.

This activity is intended for oncologists, otolaryngologists, and pathologists on the SCCHN care team.

Learning Objectives:

• Have increased knowledge regarding the
  • Current treatment paradigm for metastatic SCCHN
  • Key clinical trial data evaluating immune-modulating therapies for the treatment of SCCH
• Demonstrate greater confidence in their ability to
  • Integrate key clinical trial data into practice for the treatment of patients with SCCHN 

Approximate Time to Complete: 30 minutes

Credit Available: February 24, 2022 - February 24, 2023

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

This course is no longer available for credit.

Published 10/07/2021

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Microsatellite Instability or Tumor Mutational Burden-High Cancers, provides an overview of immunotherapy treatment for cancers with these characteristics. This course will help the learner understand what microsatellite instability (MSI)  and tumor mutational burden (TMB) terms mean, what meaures can be performed to identify MSI/TMB, various FDA-approved regimens for cancers that are MSI/TMB-high, and provide current clinical trial information.    Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy for the treatment of cancers with high or low microsatellite instability and/or tumor mutational burden.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available: October 7, 2021 - October 7, 2022

Estimated time to complete activity: 30 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Define the meaning of microsatellite instability and tumor mutational burden.
• Identify the methods used to measure MSI or TMB.
• Describe the rationale for common approaches to cancer immunotherapy with MSI/TMB measures identified.

Faculty
Dung Le, MD

Associate Professor, GI Medical Oncology

Sydney Kimmel Cancer Care Center, Johns Hopkins University

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Dung Le, MD: Consulting Fees: Merck, Bristol Myers Squibb, Janssen, Nouscom.   Contracted Research: Merck, Bristol Myers Squibb, Aduro Biotech, Medivir, Curegenix, Nouscom

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period 10/7/2021 through 10/7/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-3027-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

Published 3/15/2022

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program.  Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Head and Neck Cancer, provides an overview of immunotherapy treatment for head and neck cancers. Multiple clinical trials dealing with head and neck cancers are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for head and neck cancers.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available:  March 15, 2022 - March 15, 2023

Estimated time to complete activity:  30 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Implement cancer immunotherapy treatment for head and neck cancer.
• Identify immune-related toxicities related to head and neck cancer immunotherapy agents, and also used in combination with chemotherapy agents.
• Describe the rationale for common approaches to cancer immunotherapy.

Faculty
Anshu Giri, MD, MS

Assistant Professor, Department of Hematology/Oncology

Fox Chase Cancer Center

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Anshu Giri, MD, MS: Nothing to disclose. 

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period 3/15/2022 through 03/15/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.4 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-109-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published: 3/1/2022

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Gastrointestinal Cancers, provides an overview of immunotherapy treatment for hepatocellular, colorectal, and other gastrointestinal malignancies. Multiple clinical trials dealing with these types of cancer are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for gastrointestinal cancers.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available:  March 1, 2022 - March 1, 2023

Estimated time to complete activity:  30 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Implement cancer immunotherapy treatment for gastrointestinal cancer.
• Identify various studies that are stil ongoing as well as completed clinical trials which have resulted in approvals by disease state.
• Describe the rationale for common approaches to cancer immunotherapy.

Faculty
Aiwu Ruth He, MD, PhD

Associate Professor of Medicine, Medstar Georgetown University Hospital

Georgetown University

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Aiwu Ruth He, MD, PhD:  Consulting Fees: Merck, Bayer, BMS, Aztrazeneca; Fees for Non-CE Service: Eisai, BMS, Exelixis; Contracted Research: Merck, Genentech

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number  - JA4008162-9999-22-082-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 11/1/2021

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Genitourinary Malignancies, provides an overview of immunotherapy treatment for renal cell carcinoma, urothelial carcinoma, and prostate cancer. Multiple clinical trials dealing with all three cancer types are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for these cancers.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available: November 1, 2021 - November 1, 2022

Estimated time to complete activity:  30 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Implement cancer immunotherapy treatment for renal cell carcinoma, urothelial carcinoma, and prostate cancer.
• Identify clinical trials relating to these cancers, as well as the FDA-approved treatments for each.
• Describe the rationale for common approaches to cancer immunotherapy.

Faculty
Mehmet Asim Bilen, MD

Genitourinary Medical Oncologist

Emory University, Atlanta, GA

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Mehmet Asim Bilen, MD - Consulting Fees: Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, and Sanofi; Grants to the institution - Xencor, Bayer, Bristol-Myers Squibb, Genetech/Roche, Seattle Genetics, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer.

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period 11/1/2021 through 11/1/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.2 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-3074-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 04/25/2022

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Skin Cancers, provides an overview of immunotherapy treatment for various forms of skin cancer. Multiple clinical trials are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for skin cancer.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available:  April 25, 2022 - April 25, 2023

Estimated time to complete activity:  45 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Implement cancer immunotherapy treatment for skin cancer.
• Identify FDA-approved immunotherapy treatments for skin cancer.
• Describe the rationale for common approaches to cancer immunotherapy.

Faculty
Shailender Bhatia, MD

Associate Professor of Medical Oncology

University of Washington

Fred Hutchison Cancer Research Center, Seattle, WA

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Shailender Bhatia, MD: Consulting Fees: Genentech, BMS, EMD-Serono, Sanofi-Genzyme, Exicure.   Contracted research: BMS, EMD-Serono, Immune Design, Merck, Novartis, Oncosec, Nantkwest, Exicure, Nektar, CheckMate, Xencor, Trisalus.

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period 04/25/2022 through 04/25/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.4 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-235-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published March 1, 2022

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

In this course, Toxicity Management, learners will be given information on the incidence, onset, severity and grading of immune-related toxicities; as well as immune-related adverse events with immune checkpoint inhibitors.  Dr. Jarushka Naidoo will also discuss cellular therapy adverse events and their management and discuss immunotherapy in special patient populations.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available: March , 2022 - March 1, 2023

Estimated time to complete activity: 45 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify immune-related toxicities by grade, onset, and incidence.
• Identify immune-related adverse events resulting from immune checkpoint inhibitors.
• Describe the adverse events and management of cellular therapies.
• Describe the precautions needed when immunotherapy is provided to special patient populations.

Faculty
Jarushka Naidoo, MBBCh

Assistant Professor of Oncology and Attending Physician

Sydney Kimmel Cancer Center, Johns Hopkins University

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Jarushka Naidoo, MBBCh: Consulting Fees: Astrazeneca, Bristol Meyers-Squibb, Roche/Genetech.  Non-CME Services: Merck,  Bristol Myers-Squibb, Astrazeneca.  Contracted Research: Astrazeneca, Merck.

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162 - 9999-22-083-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published: March 1, 2022

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Basic Principles will walk the learner through the biological foundations of immunotherapy, types of immunotherapies, illustrate how biomarkers play a major role in immunotherapy, as well as cover the patient response to immunotherapy and subsequent physician assessment.  

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available:  March 1, 2022 - March 1, 2023

Estimated time to complete activity:  45 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify key biological concepts of immunotherapy
• Describe the various types of immunotherapy
• Describe how biomakers play a key role in immunotherapy
• Describe how to assess the patient response to immunotherapy

Faculty
Stefani Spranger, PhD

Assistant Professor of Biology

The Koch Institue for Integrative Cancer Research, Massachusetts Institue of Technology

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Stefani Spranger, PhD: Consulting Fees: Arcus, Tango, Takeda, Ribon, Merck, Dragonfly.

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-081-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 6/25/2021

Course description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Hematologic Malignancies, provides an overview of the various treatment approaches to hematologic malignancies. This module will provide an overview of the major immunotherapies in development, FDA-approved treatments as well as the side effects associated with those treatments, and current clinical trials.  Learners will have an opportunity to apply what they've learned through two case studies.  By the end of the course, participants will be better able to implement immunotherapy for the treatment of hematologic malignancies.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available:  June 25, 2021 - June 25, 2022

Estimated time to complete activity: 45 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Discuss the purpose of immune checkpoint inihibitors, as well as identify which have been approved by the FDA.
• Recognize antibody-drug conjugates (ADCs), which have been FDA-approved, and appropriate malignancies for which ADCs would be effective.
• Identify bispecific antigens' role in immunotherapy.
• Describe cellular therapies, including CAR T cell therapies and the side effects, current FDA approvals, and clinical trials in development.

Faculty
Hongtao Liu, MD, PhD

Associate Professor of Medicine

Co-Director, Combined Apheresis Unit

Medical Director, Clinical Cellular Labratory Section of Hematology/Oncology

Department of Medicine, University of Chicago

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Hongtao Liu, MD, PhD - Consulting Fees: Agios Pharmaceuticals; BeiGene, NGM Biopharmarmaceuticals. Contracted Research: BMS; Karyopharm, Miltenyi.

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period 6/25/2021 through 6/25/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-2839-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published July 28, 2021

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, What's Next in Cancer Immunotherapy, provides an overview of several publications researching the conditions and stresses of the tumor microenvironment, as well as discussing some of the major factors impacting those providing and receiving immunotherapy treatments.  At the end of this course, participants have a better understanding not only of stress sensor impacting tumor cell growth, but also some of the major hurdles affecting immunotherapy's progression. 

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available:  July 28, 2021 - July 28, 2022

Estimated time to complete activity: 45 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify three stress sensors impacting the endoplasmic reticulum.
• Explain why targeting the cell's response to these stress sensors may be the key to immunotherapy treatments.
• Identify several of the major hurdles impacting current and future cancer immunotherapy.

Faculty
Jessica Thaxton, PhD, MsCR

Assistant Professor

Hollings Cancer Center, Medical University of South Carolina

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Jessica Thaxton, PhD, MsCR: Research grants TEVA Pharmaceuticals

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period 7/28/2021 through 7/28/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-2862-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

Originial publish date: May 21, 2021

PLEASE NOTE: This course is no longer available for CE credit.  To see a list of courses available for credit, please click HERE for a complete listing.

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Lung Cancer, provides an overview of immunotherapy treatment for lung cancer. Multiple clinical trials dealing with both non-small cell lung cancer and small cell lung cancer are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for lung cancers.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available:  May 21, 2021 - May 21, 2022

Estimated time to complete activity: 45 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Implement cancer immunotherapy treatment for lung cancer.
• Identify immune-related toxicities related to lung cancer immunotherapy agents.
• Describe the rationale for common approaches to cancer immunotherapy.

Faculty
Jennifer Carlisle, MD

Assistant Professor

Emory University

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Jennifer Carlisle, MD: Nothing to disclose.

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period 5/21/2021 through 5/21/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.4 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-2718-H01)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

Original publish date: May 13, 2021.  Please note: this course is no longer available for CE credits. 

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer's (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at https://www.sitcancer.org/education/aci/online.

This course, Immunotherapy for the Treatment of Breast and Gynecologic Cancers, provides an overview of the currently-approved treatments used to treat both breast and gynecologic cancers, as well as a synopsis of future potential applications of immunotherapy for these cancers.  Several clinical trials and two case studies are discussed, allowing the learner to better understand the current use of immunotherapy as well as how clinical trials are leading the way to additional use of immunotherapy for both types of cancer.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available: May 13, 2021 - May 13, 2022

Estimated time to complete activity: 30 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the early stage application of breast and gynecologic cancer immunotherapy treatment in relation to standard-of-care therapies
• Select cancer immunotherapy treatment for breast and gynecologic cancer and better manage common side effects
• Describe the rationale for common approaches to cancer immunotherapy

Faculty
Megan Kruse, MD

Associate Staff Physician

Hematology and Medical Oncology

Cleveland Clinic

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Megan Kruse, MD: Consulting Fees: Puma biotechnology, Immunomedics, Eisai, Seattle Genetics, Lilly Oncology, Novartis Oncology.   Contracted Research: Tempus.

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 
 

Method of Participation and Request for Credit
During the period 5/13/2021 through 5/13/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-2714-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

Join this interprofessional panel as they discuss the management of triple-negative breast cancer using immunotherapeutic agents.

The goal of this initiative is to improve the knowledge and competence of oncologists, nurses/nurse practitioners (NPs), and pharmacists in safely and effectively implementing immune checkpoint inhibitors for eligible patients with triple-negative breast cancer (TNBC).

This activity is intended for oncologists, obstetricians and gynecologists, pathologists, nurses, and pharmacists.

Learning Objectives:

• Have increased knowledge regarding the
  • Clinical trial data on the use of immune checkpoint inhibitor (ICI) regimens in patients with triple-negative breast cancer (TNBC) across the spectrum of disease
• Have greater competence related to
  • Identifying patients who may be appropriate candidates for checkpoint inhibition
  • Using a team-based approach to managing immune-related adverse events of ICIs in TNBC

Approximate Time to Complete: 45 minutes

Credit Available: May 7, 2021 - May 7, 2022

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

Dr. Ranee Mehra examines the use of immune checkpoint inhibitors in two patients with NSCLC. The goal of this activity is to improve clinicians' ability in managing patients with metastatic non-small cell lung cancer (mNSCLC) on immune checkpoint inhibitors (ICIs).

The presented cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.

This activity is intended for oncologists, pulmonologists, and pathologists.

Learning Objectives:

• Have increased knowledge regarding the
  • Clinical trial data on the use of ICIs in patients with mNSCLC whose tumor does not contain an actionable mutation
• Have greater competence related to
  • Identifying the necessary immunotherapeutic biomarkers to help guide first-line treatment decisions in patients with mNSCLC without actionable mutations
  • Choosing the most appropriate first-line ICI regimen for a patient with mNSCLC without actionable mutations
  • Management of adverse events in patients receiving front-line therapy for mNSCLC without actionable mutations

Approximate Time to Complete: 60 minutes

Credit Available: April 20, 2021 - April 20, 2022

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" (Published July 17, 2018)

View Guidelines Here.

View On-Demand Webinar Here.

Join Dr. Yeku for a discussion on novel and emerging immunotherapeutic regimens for the management of gynecologic cancers.

The goal of this activity is to explore and understand the rationale and current and potential role of immunotherapy in the treatment of gynecologic cancers.

This activity is intended for oncologists, obstetricians, gynecologists, and pathologists.

Learning Objectives:

• Have increased knowledge regarding the
  • Clinical trial data around the use of immune checkpoint inhibitor (ICI) regimens in women with gynecological cancers
  • Role of immunotherapeutic biomarkers in women with gynecological cancers
  • Patients with gynecological cancer in whom an immune checkpoint inhibitor regimen should be considered

Approximate Time to Complete: 30 minutes

Credit Available: April 8, 2021 - April 8, 2022

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices—order from thousands of labs, diagnoses, devices, and drugs using an intuitive patient chart-based interface. Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.

The goal of this activity is to provide clinicians with the latest data and concepts regarding the diagnosis and treatment of and adverse event management for patients with bladder cancer.

This activity is intended for hematology/oncology specialists and urologists.

Learning Objectives:

• Demonstrate improved performance associated with
  • Determining appropriate treatment strategies for bladder cancer
  • Selecting therapy for a patient with non-muscle invasive bladder cancer (NMIBC)
  • Selecting therapy for a patient with metastatic bladder cancer 
  • Providing strategies to monitor or manage immune-related adverse events 

Approximate Time to Complete: 75 minutes

Credit Available: March 29, 2021 - March 29, 2022

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

Join Drs Catenacci and Uboha for an expert discussion on the role of immunotherapy in gastric/GEJ cancers.

The goal of this activity is to inform clinicians about the current indications and guideline recommendations for immunotherapy in gastric/gastroesophageal junction cancers, and discuss ongoing clinical trials.

This activity is intended for oncologists, gastroenterologists, and pathologists.

Learning Objectives:

• Have increased knowledge regarding the
  • Immunotherapy-based treatment in the management of gastric/GEJ cancers
• Have greater competence related to
  • Identifying patients for immunotherapy-based treatment in the appropriate clinical setting reflective of biomarkers and previous treatments

Approximate Time to Complete: 30 minutes

Credit Available: April 5, 2021 - April 5, 2022

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC:

In this activity, join expert faculty for a discussion on emerging immunotherapy strategies for esophageal and hepatocellular carcinomas.

The goal of this activity is to improve oncologists’ ability to integrate immune checkpoint inhibitors into the care of unresectable hepatocellular carcinoma (HCC) and esophageal cancer.

This activity is intended for oncologists, gastroenterologists, and pathologists.

Learning Objectives:

• Have increased knowledge regarding the
  • Role of immunotherapy in esophageal cancer
  • Clinical data for immunotherapy use in unresectable HCC
• Have greater competence related to the
  • Identification of appropriate candidates for treatment with immune checkpoint inhibitors in patients with HCC
  • Integration of immune checkpoint inhibitors for patients with esophageal cancer

Approximate Time to Complete: 45